Provided by Tiger Trade Technology Pte. Ltd.

Summit Therapeutics PLC

16.76
+0.06500.39%
Post-market: 16.820.0611+0.36%19:59 EDT
Volume:5.20M
Turnover:87.53M
Market Cap:13.37B
PE:-14.99
High:17.32
Open:16.96
Low:16.66
Close:16.69
52wk High:29.23
52wk Low:12.07
Shares:797.75M
Float Shares:152.34M
Volume Ratio:0.45
T/O Rate:3.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1177
EPS(LYR):-1.4439
ROE:-192.50%
ROA:-101.61%
PB:21.22
PE(LYR):-11.60

Loading ...

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)

TIPRANKS
·
Sep 14

Summit partner announces updated data from Phase III HARMONi-2 trial

TIPRANKS
·
Sep 13

Summit Therapeutics Advances Ivonescimab Combo Into Pivotal Bladder Cancer Trial

TIPRANKS
·
Sep 12

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
Sep 10

U.S. Stocks on the MOVE-UGI, Chewy, Cognyte Software

Reuters
·
Sep 09

U.S. Stocks on the MOVE-Meta, Chime Financial, ServiceTitan

Reuters
·
Sep 09

Jefferies Upgrades Summit Therapeutics to "buy", Shares Up

Reuters
·
Sep 09

Summit Therapeutics Inc. : Jefferies Raises to Buy from Hold; Raises Target Price to $25 from $15

THOMSON REUTERS
·
Sep 09

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Royalty Pharma (RPRX) and Summit Therapeutics (SMMT)

TIPRANKS
·
Sep 08

Shimamura Co Ltd - Notice Concerning Acquisition of Business

Reuters
·
Sep 07

Summit Therapeutics Says it is Beating Merck with Its Cancer Drug

Dow Jones
·
Sep 04

Summit Therapeutics Stock (SMMT) Rallies on Positive Clinical Trial Results

TIPRANKS
·
Sep 03

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in Pd-L1-Positive Advanced Nsclc in Harmoni-2 Study Conducted by Akeso in China

THOMSON REUTERS
·
Sep 03

Summit Therapeutics Inc Stock (SMMT) Moved Up by 8.95% on Aug 26: Drivers Behind the Movement

TradingKey
·
Aug 26

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

MT Newswires Live
·
Aug 26

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release

MT Newswires Live
·
Aug 26

Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints

MT Newswires Live
·
Aug 26

Summit: Akeso reports ‘positive’ results from Phase III HARMONi-GI11 study

TIPRANKS
·
Aug 26

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

THOMSON REUTERS
·
Aug 26

Summit Therapeutics - Study Meets Key Secondary Endpoints of Pfs and Orr

THOMSON REUTERS
·
Aug 26